"There seems to be a broad range of sensitivity to the medications among different people." In practical terms, that means a lower dose may still help with appetite, food noise and weight loss but results may be slower, less predictable or insufficient compared with the regimens that have actually been studied
[33] In February 2018, authorization was granted in the European Union, [16] [86] in March 2018 in Japan, [34] and in August 2019 in Australia
These infected tissues, when not controlled by the adaptive response, could end up with chronic inflammation due to the activation of TLR3 receptors or RIG-I, which results in continuous detection of viral genetic material (EBERs) [231,232,233], causing a chronic innate response and inflammation through the continuous release of proinflammatory cytokines, generating an increase in IL-1, IL-6, TNF and IFN- in individuals with ME/CFS [37]
You deserve medication that works exactly as intended